EyePoint Pharmaceuticals Appoints John Weet to SVP, Regulatory Affairs Post


WATERTOWN, Mass.—EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, has appointed John Weet, PhD, as senior vice president, regulatory affairs and quality. Weet has more than 40 years of experience in regulatory affairs and he has extensive expertise in the oversight of Food and Drug Administration relations and negotiations across multiple therapeutic areas, including ocular disease, according to an announcement this week. “We are delighted to welcome Dr. Weet, a proven regulatory affairs executive, to the growing EyePoint team,” Nancy Lurker, president and chief executive officer of EyePoint, said in the announcement.

She continued, “His extensive knowledge and experience navigating the complex regulatory environment will be invaluable as we approach our PDUFA date for Yutiq on Nov. 5, 2018."

Weet noted that it is “an exciting time for EyePoint, with the launches of both Dexycu and, if approved, Yutiq, anticipated in 2019. I look forward to the work ahead, and to joining forces with the seasoned management team already at the helm.”

Prior to joining EyePoint, Dr. Weet served as vice president, regulatory affairs and quality assurance at Collegium Pharmaceutical. He also previously served as vice president, global regulatory affairs at Bausch + Lomb, a subsidiary of Bausch Health.

EyePoint Pharmaceuticals was formerly known as pSivida Corp.